Startups
Our foundation supports the transfer of innovation from medical research to industry, in particular through young entrepreneurship in Switzerland. The foundation aims to strengthen Basel and Switzerland as a scientific and business location, also for the benefit of future generations. We invest in companies in Switzerland or abroad that are active in the field of […]
Mentions in press and media 5
| Date | Title | Description |
| Sign up to see | Sign up to see | Sign up to see |
| Jan 9, 2026 | CHF 10 million seed funding and new board chair for TECregen | Alongside the Boehringer Ingelheim Venture Fund (BIVF) TECregen’s funding round saw participation from LifeSpan Vision Ventures, Carma Fund, EOS BioInnovation, High-Tech Gründerfonds (HTGF), the JFG Life Sciences Foundation of the Univers... |
| Jun 19, 2024 | NXI Therapeutics extends pre-seed financing to CHF 3.5 million | NXI Therapeutics, a spin-off from the Biozentrum at University of Basel, is committed to creating tomorrow’s disruptive immunotherapies through modulation of coronin 1 in immune cells. Coronin 1 depletion in preclinical models allows long-... |
| Jun 7, 2022 | Invasight closes CHF 4.5 million oversubscribed seed round | June 7, 2022 |
| Jun 7, 2022 | Invasight closes CHF 4.5 million seed round to fight invasive cancers |
Reviews 0
FAQ about jfgstiftung.ch
What has the press written about jfgstiftung.ch?
Parsers VC has collected 5 articles mentioning jfgstiftung.ch, among them “CHF 10 million seed funding and new board chair for TECregen” (Jan 9, 2026) and “NXI Therapeutics extends pre-seed financing to CHF 3.5 million” (Jun 19, 2024).
Is jfgstiftung.ch still active?
Yes, jfgstiftung.ch is active; its latest activity on Parsers VC dates from Jan 9, 2026.